Absolute Bioavailability of Intranasal Fluticasone Furoate in Healthy Subjects
References (10)
- et al.
Relationship between systemic corticosteroid exposure and growth velocity: Development and validation of a pharmacokinetic/pharmacodynamic model
Clin Ther
(2004) Systemic adverse effects of inhaled corticosteroid therapy: A systemic review and meta-analysis
Arch Intern Med
(1999)- et al.
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
EurJ Clin Pharmacol
(2004) - et al.
Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects
Ann Allergy Asthma Immunol.
(2007) A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of 2 and 3 m GW685698X (2000 g), FTIM GW685698X material (2000 g) and FP (1000 g) administered via Diskhaler in healthy male subjects
(2003)
Cited by (53)
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate: Pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate
2022, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Lower systemic bioavailability following inhalation has been reported for MF, but MF also has a greater number of metabolites including active metabolites [11,18,19]. In contrast, following administration as an aqueous nasal spray, all three molecules have similar bioavailability, pharmacokinetics (PK) and systemic pharmacodynamics (PD) [20,21]. A report of very low (<1%) systemic bioavailability following inhaled administration of MF may be as a consequence of the low single dose studied together with the relatively insensitive assay used to detect MF in plasma [14,22].
Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration
2022, International Journal of PharmaceuticsCitation Excerpt :Extremely low aqueous solubility is known to result in low oral bioavailability (Boyd et al., 2019) but it will also result in low nasal bioavailability, as shown for low solubility steroids such as fluticasone propionate (McDowall et al., 1997), fluticasone furoate (Allen et al., 2007) and mometasone furoate (Hochhaus, 2008). The absorption directly in the nose is limited by the poor solubility because the nasal mucosal contact time is limited (Allen et al., 2007) and most of the drug is therefore cleared by the nasal cilia and swallowed before dissolution occurs (Daley-Yates, 2001). The swallowed dose will however also be poorly absorbed orally due to the extremely low solubility and the contribution to the systemic exposure will therefore be negligible of the dose trapped by the intranasal filtration.
Safety of intranasal corticosteroids for allergic rhinitis in children
2022, Expert Opinion on Drug SafetyEfficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays
2021, International Forum of Allergy and RhinologyIntranasal corticosteroids: Topical potency, systemic activity and therapeutic index
2021, Journal of Asthma and Allergy